



GMMM Interface Prescribing
Subgroup



Agenda

12th February 2015, 1pm-3pm

HMR CCG

Room 410, Number One Riverside, Smith St. Rochdale OL16 1XU

[Declarations of Interest](#) (new declarations only)

Apologies:

	ENC
1) Draft Minutes of 8th January 2015	Item 1
2) Matters Arising <ul style="list-style-type: none"> a) Domperidone Paediatric Use – RAG status b) RAG List Recommendations Oct meeting – awaiting GMMM approval c) RAG List Recommendations Chapter 4 – awaiting GMMM approval d) RAG List Recommendations from January meeting (Modafinil, Ranolazine, Fosfomycin, Ulipristal, Tolcapone) – comments received e) Chapter 9 SCP Review - hydroxycarbamide f) Chapter 9 SCP Review – cinacalcet for primary hyperparathyroidism g) Chapter 5 SCP Review – colistimethate for non-CF patients h) Chapter 4 SCP Review i) Archive section for SCPs on GMMM website 	Item 2a Item 2d
3) Chapter 6 RAG list review – drugs for review <ul style="list-style-type: none"> a) Infertility Drugs – currently Red b) Denosumab – currently Amber c) GLP-1 agonists – currently Green d) Growth hormone (children) - currently Amber – no SCP currently e) Growth hormone (adults) – currently Amber f) Ibandronic acid (breast cancer) – currently Amber g) Insulin + GLP-1 – currently Green (following specialist initiation) h) LHRH analogues – currently Amber for licensed indications i) Metformin for PCOS – currently Green 	Item 3

- j) Pegvisomat – **currently Amber – NHSE commissioned but only via IFR – no SCP in place**
- k) Propylthiouracil - **currently Green (following specialist initiation)**
- l) Gliptins – **currently Green**
- m) Stanozolol – **currently Red**
- n) Testosterone products – **currently Green**
- o) Tolvaptan – **currently Red**
- p) Cyproterone – **no status**
- q) Epotermin alfa (Osigraft®) – **no status**
- r) Disodium pamidronate – **no status**
- s) Zolendronic acid – **no status**
- t) Teriparatide – **no status**
- u) Parathyroid hormone – **no status**

4) Chapter 6 Shared Care Protocol review – existing guidelines

Document Title	BNF	Organisation	Date	Review date	In GMMMG Format
Growth Hormone in Adults	6	Pennine Acute	Mar 2013	Mar-15	Yes
Ibandronate (Bondronat®) in metastatic breast cancer	6	The Christie	Apr 2010	Apr-12	No

Item 4(i)
Item 4(ii)

5) Chapter 6 Shared Care Protocol review – drugs without an SCP

- a) Growth hormone for children
- b) Denosumab
- c) Pegvisomat for acromegaly
- d) Goserelin for licensed indications in women

6) Chapter 11 RAG list review – drugs for review

- a) Currently no drugs classified as Red or Amber
- b) Aflibercept – no status
- c) Ranibizumab intravitreal injection – no status
- d) Pegaptanib sodium – no status
- e) Vertoporphin – no status
- f) Bevacizumab (Avastin®) – no status (unlicensed)
- g) Ocriplasmin intravitreal injection – no status
- h) Dexamethasone intravitreal implant – no status
- i) Fluocinolone acetonide intravitreal implant – no status
- j) Apraclonidine eye drops – no status (licensed)
- k) Ketoralac eye drops – no status (licensed)
- l) Sodium chloride 5% eye drops – no status (licensed)
- m) Ofloxacin eye drops – no status (licensed)
- n) Cefuroxime eye drops – no status (unlicensed)

Item 5(i)
Item 5(ii)

<p>o) Levofloxacin eye drops – no status (licensed)</p> <p>p) Gentamicin eye drops – no status (licensed)</p> <p>q) Penicillin eye drops – no status (unlicensed)</p> <p>r) Amikacin eye drops – no status (unlicensed)</p> <p>s) Propamide eye drops – no status (licensed)</p> <p>t) Dibromopropamide eye ointment – no status (licensed)</p> <p>u) PHMB eye drops – no status (unlicensed)</p> <p>v) Chlorhexidine eye drops – no status (unlicensed)</p> <p>w) Ganciclovir 1.5% eye drops – no status (unlicensed)</p> <p>x) Ganciclovir 0.15% gel – no status (licensed)</p> <p>y) Trifluorothymidine eye drops – no status (unlicensed)</p> <p>z) Fluorometholone eye drops – no status (licensed)</p> <p>aa) Acetazolamide tablets – no status (licensed)</p> <p>bb) Steroid Preservative free eye drops – no status (unlicensed)</p>	
<p>7) Chapter 11 Shared Care Protocol review – existing guidelines None</p>	
<p>8) Antidementia drugs information leaflet</p>	Item 8 i-v
<p>9) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status None</p>	
<p>10) Shared Care Protocols for Approval None</p>	
<p>11) Forward work plan</p>	Item 11
<p>12) Updates from other groups</p>	
<p>a) Formulary Subgroup (verbal)</p>	
<p>b) New Therapies Subgroup (verbal)</p>	
<p>c) GMMMG (verbal)</p>	
<p>13) AOB Valproate RAG status in epilepsy following MHRA DSU Jan 2015</p>	
<p>14) Date of Next Meeting: 12th March 2015, 1pm-3pm, Meeting Room 1 Croft Shifa health Centre, Belfield Rd , Rochdale, OL16 2UY</p>	